Creative Diagnostics has announced the expansion of its comprehensive range of Products for Hepatic Metabolism, providing pharmaceutical researchers and toxicologists with new tools for critical in vitro metabolism studies. The liver plays a central role in human metabolism, processing both beneficial and harmful substances through carbohydrate, lipid, protein, and drug metabolism pathways. Most liver diseases result in hepatocyte damage that profoundly affects these metabolic processes.
The liver serves as the primary organ for drug metabolism and the main site of drug-induced toxicity, accounting for over 50% of acute liver failure cases that lead to medication withdrawals or restrictions. Beyond hepatotoxicity, metabolites generated in the liver circulate systemically to other tissues and organs including kidneys, heart, brain, intestines, lungs, and tumors. These liver-organ interactions can produce desired therapeutic effects but may also lead to unintended toxic side effects, as demonstrated by the pre-chemotherapy drug ifosfamide which produces both antitumor and nephrotoxic metabolites.
The company now offers an extensive range of hepatic metabolism products that enable researchers to study hepatic metabolic processes with high precision and reproducibility. This new product line includes liver products from various species including humans, non-human primates, dogs, rats, rabbits, and minipigs, with core products consisting of Liver Cytosol, Liver Microsomes, and Liver S9 Fractions. According to the Creative Diagnostics project manager, "Precise metabolomic analysis is the cornerstone of successful drug development. By offering a liver metabolism testing product line spanning multiple species, we help our clients in the pharmaceutical industry bridge the gap between in vitro testing and in vivo outcomes, ultimately reducing the risk of clinical failure."
Drug metabolism studies remain essential during drug evaluation processes, and the expanded product portfolio aims to address challenges encountered during drug development. Researchers can learn more about the full catalog of Products for Hepatic Metabolism by visiting the company's website. The company provides comprehensive metabolic research solutions that support the quality control of biologics while offering analytical methods and applications for the biotechnology and biopharmaceutical industries.
This expansion matters because it directly addresses a critical bottleneck in drug development: the high failure rate due to unforeseen toxicity. By providing tools that more accurately predict how drugs are metabolized and how metabolites affect other organs, Creative Diagnostics helps researchers identify potential safety issues earlier, potentially reducing the cost and time of bringing new therapies to market. For the New York City metro area, which hosts a significant concentration of pharmaceutical and biotech firms, access to such advanced research tools could accelerate local drug development efforts and enhance the region's position as a hub for biomedical innovation.
